Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
09:32 ET | 505 | 3.84 |
10:01 ET | 649 | 3.85 |
10:26 ET | 200 | 3.85 |
10:28 ET | 300 | 3.84 |
10:30 ET | 100 | 3.84 |
10:37 ET | 300 | 3.84 |
10:39 ET | 100 | 3.81 |
10:42 ET | 400 | 3.84 |
10:44 ET | 200 | 3.8 |
10:51 ET | 200 | 3.85 |
10:55 ET | 200 | 3.81 |
11:02 ET | 100 | 3.84 |
11:06 ET | 945 | 3.825 |
11:13 ET | 800 | 3.78 |
11:38 ET | 1472 | 3.78 |
11:44 ET | 1000 | 3.73 |
11:45 ET | 100 | 3.73 |
11:47 ET | 100 | 3.74 |
12:03 ET | 100 | 3.75 |
12:05 ET | 1200 | 3.76 |
12:07 ET | 700 | 3.72 |
12:16 ET | 1964 | 3.67 |
12:34 ET | 200 | 3.69 |
12:36 ET | 200 | 3.69 |
12:38 ET | 200 | 3.66 |
12:54 ET | 115 | 3.64 |
01:08 ET | 1000 | 3.63 |
01:21 ET | 600 | 3.63 |
01:24 ET | 250 | 3.61 |
01:26 ET | 100 | 3.635 |
01:48 ET | 2691 | 3.56 |
01:57 ET | 200 | 3.6135 |
02:27 ET | 300 | 3.67 |
02:36 ET | 1811 | 3.74 |
03:57 ET | 200 | 3.68 |
03:59 ET | 100 | 3.77 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 210.9M | -1.8x | --- |
Elevation Oncology Inc | 210.4M | -2.3x | --- |
Design Therapeutics Inc | 210.2M | -2.9x | --- |
Merrimack Pharmaceuticals Inc | 214.2M | -178.5x | --- |
Outlook Therapeutics Inc | 202.9M | -2.2x | --- |
Trevi Therapeutics Inc | 202.7M | -10.0x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $207.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-2.05 |
Book Value | $4.32 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.